Cancer News and Research

Latest Cancer News and Research

ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer patients

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.

1 Jul 2010

Rexahn closes sale of $10 million of securities in registered direct offering

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the closing of a previously announced sale of an aggregate of $10 million of securities in a registered direct offering. Rexahn received net proceeds of approximately $9.28 million after deducting placement agent fees and other offering expenses.

1 Jul 2010

Bisphenol A (BPA) containing baby bottles to be phased out

Federal Parliamentary Secretary for Health Mark Butler has announced that following public concern and a safety review ordered by US health regulators, the phase out will begin from today. He also revealed that according to Food Standards Australia New Zealand intake levels are very low and do not pose a risk to babies' health.

1 Jul 2010

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.

1 Jul 2010

Bortezomib may offer hope for treating inflammatory diseases: New research

Those looking for a new treatment for a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory bowel disease, and lupus may need to look no further than a drug already available for treating cancer. In a research report published in the July 2010 print issue of the Journal of Leukocyte Biology, Japanese scientists use mice to show that bortezomib, currently used to treat cancers that affect white blood cells, induces cell death only in harmful (active and proliferating) T cells, leaving the rest unharmed.

1 Jul 2010

Key mechanism present in virgin olive oil protects body against breast cancer: Researchers

Researchers at Universitat Autònoma de Barcelona, led by Dr Eduard Escrich, have discovered a key mechanism by which virgin olive oil, in contrast to other vegetable oils, protects the body against breast cancer.

30 Jun 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Calistoga Pharmaceuticals closes $40 million Series C financing

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.

30 Jun 2010

Proton Therapy USA, CareCapital form Proton Therapy Global Management

Proton Therapy USA and CareCapital plc announced today the formation of Proton Therapy Global Management (PTGM). The Company will design, develop and manage a global network of proton therapy centers, providing access to this specialized and highly effective treatment to the world's growing population of cancer patients. Proton therapy is a precise form of radiation treatment that has been very successful in treating a wide range of localized tumors, while leaving healthy tissue mostly intact.

30 Jun 2010

SeqWright, RainDance Technologies partner to offer RainStorm microdroplet-based PCR technology

SeqWright Inc., a world-wide leader in custom genomic and molecular biology services, announced today the expansion of its service portfolio by partnering with RainDance Technologies to offer the company's innovative RainStorm™ microdroplet-based PCR technology. SeqWright recognizes the growing demand from life science researchers for more efficient and cost-effective processes that allow for automated workflows providing greater confidence in results to meet the needs of large-scale resequencing studies.

30 Jun 2010

Investment report on BioCryst Pharmaceuticals

MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

30 Jun 2010

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).

30 Jun 2010

Epigentek develops new approach for identification of "sixth DNA base" 5-hmC

Research experts in the epigenetic field from Epigentek have developed a new, breakthrough approach for the identification of the "sixth DNA base," 5-hydroxymethylcytosine (5-hmC). This technology is based on a high throughput, strip-well format and is also incorporated into the first commercially available product, the MethylFlash(TM) Hydroxymethylated DNA Quantification Kit, for rapidly quantifying hydroxymethylated DNA.

30 Jun 2010

Raptor partners with Uni Pharma to commercialize Convivia in Taiwan

Raptor Pharmaceutical Corp., announced that it has entered into an exclusive agreement with Uni Pharma Co., Ltd. to commercialize Convivia™, Raptor's proprietary oral formulation of 4-methylpyrazole, in Taiwan.

30 Jun 2010

Concord Medical board authorizes $20 million share repurchase program

Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that its board of directors approved a share repurchase program, effective immediately.

30 Jun 2010

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.

30 Jun 2010

Federal agencies, state governments take action to educate, protect against serious risks of indoor tanning

As the scientific evidence mounts, more federal agencies and state governments are taking action to educate and protect Americans against the serious risks of indoor tanning. Recent and pending legislation in numerous states restricting access to indoor tanning, along with the federal 10 percent indoor tanning tax that goes into effect on July 1, are important steps in keeping Americans safe from overexposure to ultraviolet (UV) radiation and the potential for future skin cancers.

30 Jun 2010

Excellence in Paediatrics to be held in London, from 2 - 4 December 2010

Experts from all over the world will be converging on the Park Plaza Hotel in Westminster, London, from 2 - 4 December 2010 for Excellence in Paediatrics, which promises cutting edge topics by outstanding speakers.

30 Jun 2010

Vitrified eggs as likely to produce on-going pregnancy as fresh eggs

Embryos derived from oocytes (eggs) cryopreserved by the vitrification method are just as likely to produce an on-going pregnancy as those involving fresh oocytes, the 26th annual meeting of the European Society of Human Reproduction and Embryology heard today. Dr. Ana Cobo, Cryobiology Unit director at Institut Universitari - IVI Valencia, Valencia, Spain, told delegates that the results of her team's research would make egg donation both easier and safer in the future.

30 Jun 2010

Canadian Cancer Society urges for mining, export permission denial

In a letter sent to Quebec Premier Jean Charest, the Canadian Cancer Society is urging the premier not to approve a $58 million loan guarantee to Jeffrey Asbestos Mines, based in Quebec, for the renewal of asbestos mining and export.

30 Jun 2010